{"id":"selexipag-uptravi","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Headache"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL238804","moleculeType":"Small molecule","molecularWeight":"496.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Selexipag works by binding to the IP receptor, which leads to vasodilation and improved exercise capacity in patients with pulmonary arterial hypertension. This mechanism of action is thought to be beneficial in reducing symptoms and improving quality of life for patients with this condition.","oneSentence":"Selexipag is a prostacyclin receptor agonist that acts as a selective IP receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:49.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT04914247","phase":"","title":"Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Actelion","startDate":"","conditions":"Non-healing Wound, Thromboangiitis Obliterans","enrollment":""},{"nctId":"NCT03492177","phase":"PHASE2","title":"A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2018-07-23","conditions":"Pulmonary Arterial Hypertension","enrollment":63},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT07453030","phase":"","title":"Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Caio Júlio César dos Santos Fernandes","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":30},{"nctId":"NCT07356375","phase":"","title":"Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT01106014","phase":"PHASE3","title":"Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":1156},{"nctId":"NCT00993408","phase":"PHASE2","title":"Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-04-30","conditions":"Pulmonary Arterial Hypertension","enrollment":43},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT03187678","phase":"PHASE3","title":"Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-12-04","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT04567602","phase":"","title":"A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2020-10-06","conditions":"Pulmonary Arterial Hypertension","enrollment":372},{"nctId":"NCT03496506","phase":"PHASE1","title":"A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-03-05","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT04565990","phase":"PHASE3","title":"A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study","status":"COMPLETED","sponsor":"Actelion","startDate":"2021-05-03","conditions":"Hypertension, Pulmonary","enrollment":43},{"nctId":"NCT06932198","phase":"PHASE1","title":"Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-01-09","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":14},{"nctId":"NCT04266756","phase":"PHASE1","title":"A Study of Selexipag in Healthy Male Participant","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-01-23","conditions":"Healthy","enrollment":24},{"nctId":"NCT04435782","phase":"PHASE4","title":"A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging","status":"TERMINATED","sponsor":"Actelion","startDate":"2021-07-07","conditions":"Pulmonary Arterial Hypertension","enrollment":9},{"nctId":"NCT03278002","phase":"","title":"A Registry for Patients Taking Uptravi","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-11-01","conditions":"Pulmonary Arterial Hypertension","enrollment":800},{"nctId":"NCT02558231","phase":"PHASE3","title":"The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-05-01","conditions":"Pulmonary Arterial Hypertension","enrollment":247},{"nctId":"NCT01112306","phase":"PHASE3","title":"ACT-293987 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-07-07","conditions":"Pulmonary Arterial Hypertension","enrollment":709},{"nctId":"NCT03078907","phase":"PHASE4","title":"Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-11-08","conditions":"Pulmonary Arterial Hypertension","enrollment":108},{"nctId":"NCT02770222","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT02882425","phase":"PHASE1","title":"Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-01","conditions":"Healthy Subjects","enrollment":19},{"nctId":"NCT02745860","phase":"PHASE1","title":"Comparison of Two Dose Strengths of Selexipag in Healthy Adults","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02206295","phase":"PHASE1","title":"Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-09","conditions":"Bioequivalence","enrollment":80},{"nctId":"NCT02260557","phase":"PHASE2","title":"Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-10","conditions":"Raynaud's Phenomenon Secondary to Systemic Sclerosis","enrollment":74},{"nctId":"NCT06753981","phase":"","title":"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-12-10","conditions":"Arterial Pulmonary Hypertension (PAH)","enrollment":48},{"nctId":"NCT05825417","phase":"PHASE4","title":"Pulmonary Hypertension: Intensification and Personalisation of Combination Rx","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2023-06-14","conditions":"Pulmonary Arterial Hypertension","enrollment":40},{"nctId":"NCT03689244","phase":"PHASE3","title":"A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment","status":"TERMINATED","sponsor":"Actelion","startDate":"2019-01-23","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":128},{"nctId":"NCT03942211","phase":"PHASE2","title":"A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag","status":"TERMINATED","sponsor":"Actelion","startDate":"2021-02-26","conditions":"Sarcoidosis-associated Pulmonary Hypertension","enrollment":10},{"nctId":"NCT05600218","phase":"","title":"RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists","status":"UNKNOWN","sponsor":"Hospital Costa del Sol","startDate":"2021-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":60},{"nctId":"NCT04589390","phase":"PHASE2","title":"Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-15","conditions":"Pulmonary Hypertension, Schistosomiasis","enrollment":20},{"nctId":"NCT04309838","phase":"","title":"Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-03","conditions":"Pulmonary Arterial Hypertension, PAH","enrollment":30},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT02471183","phase":"PHASE3","title":"Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-10-12","conditions":"Pulmonary Arterial Hypertension","enrollment":34},{"nctId":"NCT03016468","phase":"PHASE2","title":"Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-05","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT02791815","phase":"PHASE1","title":"Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-07","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02206204","phase":"PHASE1","title":"Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-06","conditions":"Cardiodynamics, Safety, Tolerability","enrollment":159}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HEPATIC CIRRHOSIS"},{"count":1,"reaction":"THERAPEUTIC RESPONSE UNEXPECTED"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACT-293987","JNJ-67896049"],"phase":"phase_3","status":"active","brandName":"selexipag (Uptravi)","genericName":"selexipag (Uptravi)","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selexipag, a small molecule, is used to treat Pulmonary Arterial Hypertension and Schistosomiasis-Associated Pulmonary Arterial Hypertension. It is indicated for the treatment of Pulmonary Hypertension, specifically Pulmonary Arterial Hypertension, according to ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}